{"TopicDetails": {"type": 0, "ccm2Id": 45700944, "cftId": 0, "identifier": "HORIZON-HLTH-2023-TOOL-05-08", "title": "Pandemic preparedness and response: In vitro diagnostic devices to tackle cross-border health threats", "publicationDateLong": 1670371200000, "callIdentifier": "HORIZON-HLTH-2023-TOOL-05", "callTitle": "Tools and technologies for a healthy society (Single stage - 2023)", "callccm2Id": 45702205, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108628, "abbreviation": "HORIZON.2.1.4", "description": "Infectious Diseases, including poverty-related and neglected diseases"}, {"id": 43108638, "abbreviation": "HORIZON.2.1.5", "description": "Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine"}, {"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "destinationDetails": "<p>Calls for proposals under this destination are directed towards the Key Strategic Orientation KSO-A <em>\u2018Promoting an open strategic autonomy by leading the development of key digital, enabling and emerging technologies, sectors and value chains\u2019</em> of Horizon Europe\u2019s Strategic Plan 2021-2024. Research and innovation supported under this destination should contribute to the impact area <em>\u2018High quality digital services for all\u2019 </em>and in particular to the following expected impact, set out in the Strategic Plan for the health cluster: \u2018<em>Health technologies, new tools and digital solutions are applied effectively thanks to their inclusive, secure and ethical development, delivery, integration and deployment in health policies and health and care systems\u2019</em>. In addition, research and innovation supported under this destination could also contribute to the following impact areas: <em>\u2018A competitive and secure data-economy\u2019</em>, <em>\u2018Industrial leadership in key and emerging technologies that work for people\u2019</em>, and <em>\u2018Good health and high-quality accessible health care\u2019</em>.</p><p>Technology is a key driver for innovation in the health care sector. It can provide better and more cost-efficient solutions with high societal impact, tailored to the specific health care needs of the individual. However, novel tools, therapies, technologies and digital approaches face specific barriers and hurdles in piloting, implementing and scaling-up before reaching the patient, encountering additional challenges such as public acceptance and trust. Emerging and disruptive technologies offer big opportunities for transforming health care, thereby promoting the health and well-being of citizens. Unlocking this potential and harnessing the opportunities depends on the capacity to collect, integrate and interpret large amounts of data, as well as ensure compatibility with appropriate regulatory frameworks and infrastructures that will both safeguard the rights of the individual and of society and stimulate innovation to develop impactful solutions. In addition to existing European Research Infrastructures, the European Health Data Space will promote health-data exchange and facilitate cross-border research activities. Moreover, the European Health Emergency Preparedness and Response Authority (HERA) aims to improve to improve the EU's readiness for health emergencies by supporting research, innovation and development of technologies and medical countermeasures needed against potential cross-border health threats. This destination aims to promote the development of tools, technologies and digital solutions for treatments, medicines, medical devices and improved health outcomes, taking into consideration safety, effectiveness, appropriateness, accessibility, comparative value-added and fiscal sustainability as well as issues of ethical, legal and regulatory nature.</p><p>In this work programme destination 5 has a strong focus on the personalisation of health technologies and will address the following issues:</p><p>Developing computational systems for point-of-care applications, developing and validating computational models of physiological systems and integrating health data from different sources, for better patient management and improved clinical outcomes;</p><p>Fostering translational biomedical research and advancing regenerative medicine approaches into clinical settings and manufacturing;</p><p>Preparing for potential cross-border health threats through the development of innovative in-vitro-diagnostics;</p><p>Supporting the establishment of the European Health Data Space by designing a data quality label.</p><p>In view of increasing the impact of EU investments under Horizon Europe, the European Commission welcomes and supports cooperation between EU-funded projects to enable cross-fertilisation and other synergies. This could range from networking to joint activities such as the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Opportunities for potential synergies exist between projects funded under the same topic but also between other projects funded under another topic, cluster or pillar of Horizon Europe (but also with ongoing projects funded under Horizon 2020). In particular, this could involve projects related to European health research infrastructures (under pillar I of Horizon Europe), the EIC strategic challenges on health, the European Innovation Ecosystems (EIE) interregional networks on health and EIT-KIC Health (under pillar III of Horizon Europe) or in areas cutting across the health and other clusters (under pillar II of Horizon Europe), like, for instance, with cluster 4 <em>\u201cDigital, Industry and Space\u201d</em> on digitalisation of the health sector or key enabling technologies.</p><p><u>Expected Impacts</u></p><p>Proposals for topics under this destination should set out a credible pathway towards unlocking the full potential of new tools, technologies and digital solutions for a healthy society, and more specifically to several of the following expected impacts:</p><ul level=\"0\"><li>Europe\u2019s scientific and technological expertise and know-how, its capabilities for innovation in new tools, technologies and digital solutions, and its ability to take-up, scale-up and integrate innovation in health care is world-class.</li><li>Citizens benefit from targeted and faster research resulting in safer, more sustainable, efficient, cost-effective and affordable tools, technologies and digital solutions for improved (personalised) disease prevention, diagnosis, treatment and monitoring for better patient outcome and well-being, in particular through increasingly shared health resources (interoperable data, infrastructure, expertise, citizen/patient driven co-creation)[[<sup> </sup>Commission Communication on the digital transformation of health and care; COM(2018) 233 final.]].</li><li>The EU gains high visibility and leadership in terms of health technology development, including through international cooperation.</li><li>The burden of diseases in the EU and worldwide is reduced through the development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centred solutions for health care.</li><li>Both the productivity of health research and innovation, and the quality and outcome of health care is improved thanks to the use of health data and innovative analytical tools, such as artificial intelligence (AI) supported decision-making, in a secure and ethical manner, respecting individual integrity and underpinned with public acceptance and trust.</li><li>Citizens trust and support the opportunities offered by innovative technologies for health care, based on expected health outcomes and potential risks involved.</li> </ul><p>Legal entities established in China are not eligible to participate in Innovation Actions in any capacity. Please refer to the Annex B of the General Annexes of this Work Programme for further details.</p>", "destinationDescription": "Unlocking the full potential of new tools, technologies and digital solutions for a healthy society (2023/24)", "topicMGAs": [], "tags": ["chemical threat", "pathogens", "pandemic", "innovation", "radiological threat", "diagnostic solutions", "nuclear threat", "medical countermeasures", "cross-border health threats", "epidemic", "in vitro"], "keywords": ["Surveillance", "Foresight", "Disease control", "Social sciences and humanities", "Digital Agenda", "Artificial Intelligence", "Diagnostics"], "flags": ["SSH", "FORESIGHT", "DigitalAgenda", "AI"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "HORIZON-IA HORIZON Innovation Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "12 January 2023", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["13 April 2023"]}], "latestInfos": [{"approvalDate": "Aug 9, 2023 4:04:49 PM", "lastChangeDate": "Aug 9, 2023 4:04:49 PM", "content": "<p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Call </span><span lang=\"EN-GB\" style=\"mso-bidi-font-size:&#10;10.0pt;mso-bidi-font-family:Arial;mso-font-kerning:16.0pt;mso-fareast-language:&#10;EN-US;layout-grid-mode:line;mso-bidi-font-weight:bold\">HORIZON-HLTH-2023-TOOL-05<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">We recently informed the applicants about the evaluation results for their proposals. <o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">The results of the evaluation are as follows: <o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of proposals submitted (including proposals transferred from or to other calls): 170<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of inadmissible proposals: 1<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of ineligible proposals: 1<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of above-threshold proposals: 71<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;mso-bidi-font-family:Arial\">Total budget requested for above-threshold proposals: EUR 634,646,986.</span></p>\r\n</p>"}, {"approvalDate": "Apr 13, 2023 6:46:52 PM", "lastChangeDate": "Apr 13, 2023 6:46:52 PM", "content": "<p>Call HORIZON-HLTH-2023-TOOL-05 closed on 13 April 2023. 170 proposals were submitted. The breakdown per topic is:</p>\r\n<ul>\r\n    <li>HORIZON-HLTH-2023-TOOL-05-01: 8 proposals</li>\r\n    <li>HORIZON-HLTH-2023-TOOL-05-03: 65 proposals</li>\r\n    <li>HORIZON-HLTH-2023-TOOL-05-04: 49 proposals</li>\r\n    <li>HORIZON-HLTH-2023-TOOL-05-05: 23 proposals</li>\r\n    <li>HORIZON-HLTH-2023-TOOL-05-08: 24 proposals</li>\r\n    <li>HORIZON-HLTH-2023-TOOL-05-09: 1 proposals</li>\r\n</ul>\r\n<p>Evaluation results are expected to be communicated on Friday 04 August 2023 at the earliest.</p>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3475296": [{"action": "HORIZON-HLTH-2023-TOOL-05-04 - HORIZON-RIA HORIZON  Research and Innovation Actions", "plannedOpeningDate": "12 January 2023", "deadlineModel": "single-stage", "deadlineDates": ["13 April 2023"], "budgetYearMap": {"2023": 35000000}, "expectedGrants": 4, "minContribution": 8000000, "maxContribution": 10000000, "budgetTopicActionMap": {}}], "3475299": [{"action": "HORIZON-HLTH-2023-TOOL-05-05 - HORIZON-IA HORIZON Innovation Actions", "plannedOpeningDate": "12 January 2023", "deadlineModel": "single-stage", "deadlineDates": ["13 April 2023"], "budgetYearMap": {"2023": 35000000}, "expectedGrants": 4, "minContribution": 8000000, "maxContribution": 10000000, "budgetTopicActionMap": {}}], "3475302": [{"action": "HORIZON-HLTH-2023-TOOL-05-09 - HORIZON-CSA HORIZON Coordination and Support Actions", "plannedOpeningDate": "12 January 2023", "deadlineModel": "single-stage", "deadlineDates": ["13 April 2023"], "budgetYearMap": {"2023": 4000000}, "expectedGrants": 1, "minContribution": 4000000, "maxContribution": 4000000, "budgetTopicActionMap": {}}], "3475305": [{"action": "HORIZON-HLTH-2023-TOOL-05-01 - HORIZON-RIA HORIZON  Research and Innovation Actions", "plannedOpeningDate": "12 January 2023", "deadlineModel": "single-stage", "deadlineDates": ["13 April 2023"], "budgetYearMap": {"2023": 50000000}, "expectedGrants": 5, "minContribution": 8000000, "maxContribution": 10000000, "budgetTopicActionMap": {}}], "3475308": [{"action": "HORIZON-HLTH-2023-TOOL-05-03 - HORIZON-RIA HORIZON  Research and Innovation Actions", "plannedOpeningDate": "12 January 2023", "deadlineModel": "single-stage", "deadlineDates": ["13 April 2023"], "budgetYearMap": {"2023": 50000000}, "expectedGrants": 5, "minContribution": 8000000, "maxContribution": 10000000, "budgetTopicActionMap": {}}], "3475311": [{"action": "HORIZON-HLTH-2023-TOOL-05-08 - HORIZON-IA HORIZON Innovation Actions", "plannedOpeningDate": "12 January 2023", "deadlineModel": "single-stage", "deadlineDates": ["13 April 2023"], "budgetYearMap": {"2023": 40000000}, "expectedGrants": 6, "minContribution": 5000000, "maxContribution": 7000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2023"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 \u201c<em>Unlocking the full potential of new tools, technologies and digital solutions for a healthy society</em>\u201d. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:</p><ul level=\"0\"><li>The scientific and clinical communities, including health care providers and payers, as well as regulators, health systems and patients benefit from innovative diagnostic solutions that are better suited to tackle cross-border health threats.</li><li>The scientific and clinical communities have access to novel and improved methodologies for detection of pathogens with pandemic potential in humans and for timely discovery of other health threats, such as chemical, radiological and nuclear threats, including considerations on detection in animals and environmental conditions (One Health approach).</li><li>A diverse and robust pipeline of in vitro diagnostics<sup><a target=_self href=#fn1 id=r1>[1]</a></sup> is available, increasing options for clinical deployment in case of an epidemic or pandemic.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>As shown by the COVID-19 pandemic, infectious diseases remain a major threat to health and health security in the EU and globally, this is also the case for other health threats that can be linked for instance to terror attacks. New cross-border health threats are expected to emerge in the coming years and therefore it is essential to promote advanced research of medical countermeasures that can be used to detect, prevent and treat in case of a new health emergency. One of the most important aspects in crisis preparedness times is to ensure the availability of diagnostics that can contribute to detecting and characterising health threats.</p><p>Proposals should develop and advance on new in vitro diagnostics relevant for detecting and characterising cross-border health threats and develop novel approaches to the development of medical countermeasures targeting threats identified by HERA<sup><a target=_self href=#fn2 id=r2>[2]</a></sup>.</p><p>Proposals should cover pathogens with pandemic potential in humans or other health threats, such as chemical, radiological and nuclear threats for which there are no existing diagnostics or where clinical practice could benefit from innovation. Emphasis should be put on the development of new diagnostics, innovative catch-all methodologies, or on the improvement of existing health technologies advancing diagnostics and characterisation of health threats, applying the One Health approach when relevant.</p><p>Proposals should aim to diversify and accelerate the global diagnostic research and development pipeline to tackle cross-border health threats, and to strengthen the current leading role of the EU in research and development, and therefore contributing to the work of the European Health Emergency Preparedness and Response Authority (HERA).</p><p>Attention should be paid to critical social factors such as sex, gender, age, socio-economic factors, ethnicity/migration, and disability.</p><p>Proposals should include a clear regulatory path to market in order to ensure future compliance with the legal requirements. Proposals should address several of the following areas:</p><ul level=\"0\"><li>Proof-of-concept/early studies linked e.g. to performance evaluation of new diagnostics that facilitate screening, detection of the presence or exposure to a cross-border health threat or determination of infectious/disease status through human samples, included but not limited to the list of high impact health threats identified by HERA, as well chemical, radiological and nuclear threats for which there is a lack of in vitro diagnostics or existing diagnostics have a sub-optimal performance.</li><li>Data-driven diagnostic and prognostic platforms with AI and other advanced data analytics functionalities, adaptable to respond to new and multiple pathogens/threats, e.g. covering prototype viruses.</li><li>Innovative systems linked to high sensitivity/specificity profiles adaptable for broader use should be considered, such as portable, faster, more compact or accurate devices and technologies, including the possibility to develop point of care or self-tests.</li><li>Innovative diagnostics sampling methods or samples bringing a significant improvement, such as less invasive sampling methods.</li> </ul><p>This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.</p><p>Proposals should consider the involvement of the European Commission's Joint Research Centre (JRC) in regard to its experience on the performance evaluation of in vitro diagnostic devices, with respect to the value it could bring in providing an effective interface between research activities and regulatory aspects and/or to translating research results into validated test methods and strategies fit for regulatory purpose. In that respect, the JRC will consider collaborating with any successful proposal and this collaboration, when relevant, should be established after the proposal\u2019s approval.</p><p>Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.</p>\n<p id=fn1><a  target=_self href=#r1>[1]</a><sup> </sup>As defined in Guidance on Classification Rules for in-vitro Diagnostic Medical Devices for Regulation (EU) 2017/746 MDCG 2020-16 rev.1: <a href=\"https://ec.europa.eu/health/system/files/2022-01/md_mdcg_2020_guidance_classification_ivd-md_en.pdf\">https://ec.europa.eu/health/system/files/2022-01/md_mdcg_2020_guidance_classification_ivd-md_en.pdf</a></p><p id=fn2><a  target=_self href=#r2>[2]</a><a href=\"https://health.ec.europa.eu/system/files/2022-07/hera_factsheet_health-threat_mcm.pdf\">https://health.ec.europa.eu/system/files/2022-07/hera_factsheet_health-threat_mcm.pdf</a></p>", "conditions": "<h1><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\">General conditions</span></b></span></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\">described in </span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex A</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">and </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#xA;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex E</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Horizon Europe Work Programme General Annexes.</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\"> described in Part B of the Application Form available in the Submission System.</span></span></span></span></p>\n<p>&nbsp;</p>\r\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">2. Eligible countries: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;&#xA;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">of the Work Programme General Annexes.</span></span></span></span></p>\r\n<p class=\"MsoNormal\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">A  number of non-EU/non-Associated Countries that are not automatically  eligible for funding have made specific provisions for making funding  available for their participants in Horizon Europe projects. See the  information in the </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#xA;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Horizon Europe Programme Guide</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">.</span></span></span></p>\n<p>&nbsp;</p>\r\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\"> described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#xA;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> <span lang=\"EN-US\">of the Work Programme General Annexes.</span></span></span></span></p>\n<p>In recognition of the opening of the US National Institutes of Health\u2019s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.</p>\n<p>If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).</p>\n<p>The Joint Research Centre (JRC) may participate as member of the consortium selected for funding.</p>\n<p>&nbsp;</p>\r\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b>4. Financial and operational capacity and exclusion: </b>described in </span></span></span><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex C</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> of the Work Programme General Annexes.</span></span></span></p>\n<p>&nbsp;</p>\r\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Award criteria, scoring and      thresholds</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      D</span></span></a></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">of      the Work Programme General Annexes.</span></span></span></span></p>\n<p>The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.</p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span></span></span></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Online      Manual</span></span></a>.</p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes.</span></span></span></span></p>\n<p>&nbsp;</p>\r\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#xA;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex G</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes.</span></span></span></span></p>\n<h1>&nbsp;</h1>\r\n<h1><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\">Specific conditions</span></b></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the specific topic of the Work Programme</span></span></span></span>.</p>\n<h1>&nbsp;</h1>\r\n<h1><span style=\"font-size: medium;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\"><span style=\"font-family: Arial;\">Documents</span></span></b></span></h1>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><b><span lang=\"EN-US\">Call documents:</span></b></span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-ria-ia_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Standard application form (HE RIA, IA)</span></span></a><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">&nbsp;- call-specific application form is available in the Submission System</span></span></span></span><br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-ria-ia_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form (HE RIA, IA)</span></span></a><br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\">HE <span lang=\"EN-US\">General MGA v1.0</span></span></a><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/ls-mga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><br />\r\n</span></span></a><br />\r\n<span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on clinical studies (HE)</span></span></a></span></p>\n<h2><br />\r\n<span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Additional documents:</span></b></span></span></span></h2>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-1-general-introduction_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 1. General Introduction</span></span></a><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-4-health_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><br />\r\nHE Main Work Programme 2023&ndash;2024 &ndash; 4. Health</span></span></a><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><br />\r\nHE Main Work Programme 2023&ndash;2024 &ndash; 13. General Annexes</span></span></a><br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Programme Guide</span></span></a><br />\r\n<a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"font-family: Arial;\"><span style=\"font-size: small;\">HE Framework Programme and Rules for Participation Regulation 2021/695</span></a><br />\r\n<span style=\"font-family: Arial;\"><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\"><span style=\"font-size: small;\">HE Specific Programme Decision 2021/764</span></a></span></span><br />\r\n<a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Financial Regulation</span></span></span></a><br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</span></span></a><br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</span></span></a><br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></span></span></a><br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Funding &amp; Tenders Portal Terms and Conditions</span></span></a><br />\r\n<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\" style=\"font-size: 11pt; font-family: Arial;\"><span style=\"font-size: small;\">Funding &amp; Tenders Portal Privacy Statement</span></a></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#xA;font-weight:normal;mso-bidi-font-weight:bold\"><b><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\" target=\"_blank\">Online Manual</a>&nbsp;</b></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.</span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span class=\"MsoHyperlink\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.</span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;  get guidance, practical information and assistance on participation in  Horizon Europe. There are also NCPs in many non-EU and non-associated  countries (&lsquo;third-countries&rsquo;).</span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#xA;color:#003366\">&nbsp;</span></strong><span class=\"MsoHyperlink\">&ndash; contact  your EEN national contact for advice to businesses with special focus on  SMEs. The support includes guidance on the EU research funding.</span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span class=\"MsoHyperlink\">&ndash;&nbsp;contact  the Funding &amp; Tenders Portal IT helpdesk for questions such as  forgotten passwords, access rights and roles, technical aspects of  submission of proposals, etc.</span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.</span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> and&nbsp; </span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> </span></span><span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.</p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><span style=\"font-size:&#xA;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#xA;normal;mso-bidi-font-weight:bold\">&ndash; </span></strong>consult the general  principles and requirements specifying the roles, responsibilities and  entitlements of researchers, employers and funders of researchers.</p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.</span></p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "", "staticAdditionalInfo": "", "latestInfos": [{"approvalDate": "Aug 9, 2023 4:04:49 PM", "lastChangeDate": "Aug 9, 2023 4:04:49 PM", "content": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Call </span><span lang=\"EN-GB\" style=\"mso-bidi-font-size:&#10;10.0pt;mso-bidi-font-family:Arial;mso-font-kerning:16.0pt;mso-fareast-language:&#10;EN-US;layout-grid-mode:line;mso-bidi-font-weight:bold\">HORIZON-HLTH-2023-TOOL-05<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">We recently informed the applicants about the evaluation results for their proposals. <o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">The results of the evaluation are as follows: <o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of proposals submitted (including proposals transferred from or to other calls): 170<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of inadmissible proposals: 1<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of ineligible proposals: 1<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:0cm;&#10;margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;&#10;mso-bidi-font-family:Arial\">Number of above-threshold proposals: 71<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left:18.0pt\"><span lang=\"EN-GB\" style=\"mso-bidi-font-size:10.0pt;mso-bidi-font-family:Arial\">Total budget requested for above-threshold proposals: EUR 634,646,986.</span></p>"}, {"approvalDate": "Jan 12, 2023 12:00:02 AM", "lastChangeDate": "Jan 12, 2023 12:00:02 AM", "content": "The submission session is now available for: HORIZON-HLTH-2023-TOOL-05-09(HORIZON-CSA), HORIZON-HLTH-2023-TOOL-05-05(HORIZON-IA), HORIZON-HLTH-2023-TOOL-05-08(HORIZON-IA), HORIZON-HLTH-2023-TOOL-05-03(HORIZON-RIA), HORIZON-HLTH-2023-TOOL-05-01(HORIZON-RIA), HORIZON-HLTH-2023-TOOL-05-04(HORIZON-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}